HER2 Imaging Agents via Chelator Conjugation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PET and SPECT-labeled HER2 ligands have low radiochemical yields and inefficient conjugation processes, leading to suboptimal tumor uptake and renal clearance issues, limiting their clinical applicability for HER2-associated cancer imaging.
Innovation Solution
Development of new imaging agents using isolated polypeptides conjugated with 99mTc, 67Ga, or 18F via diaminedioxime, NOTA, or linker-based chelators, which offer improved radiochemical yields and biodistribution profiles, including enhanced tumor uptake and reduced liver accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional PET and SPECT-labeled HER2 ligands are used, then HER2 imaging is achieved, but radiochemical yields are low and conjugation processes are inefficient
Solution Approach 1:
The patent introduces chelator moieties (such as NOTA, DOTA, or diaminedioxime derivatives) as intermediary components that facilitate the conjugation between radionuclides and HER2-targeting ligands. These chelators serve as mediators that enable efficient and stable radiolabeling, directly addressing the low radiochemical yield and inefficient conjugation processes of conventional ligands.
Solution Approach 2:
The patent modifies the chemical parameters of HER2 ligands by incorporating specific chelator structures with optimized coordination properties. This includes selecting chelators with appropriate stability constants, kinetic lability, and spatial configuration to enhance radiochemical yield and conjugation efficiency while maintaining target binding affinity.
2Measurement precision
If conventional HER2 ligands are used for imaging, then tumor detection is possible, but tumor uptake is suboptimal
Solution Approach 1:
The patent applies local quality modification by attaching chelator moieties to specific positions on the HER2-targeting ligand structure. This localized modification ensures that the radiolabeling occurs at optimal sites that do not interfere with the targeting moiety's binding affinity, thereby improving tumor uptake while maintaining imaging reliability.
3Object-affected harmful factors
If conventional HER2 imaging agents are used, then imaging function is provided, but liver accumulation is high
Solution Approach 1:
The patent extracts or removes the problematic property of high liver accumulation by designing chelator-ligand conjugates with optimized pharmacokinetic properties. The chelator selection and attachment strategy are specifically designed to reduce hepatic uptake and improve renal clearance, thereby reducing liver accumulation while maintaining reliable tumor imaging.
4Adaptability or versatility
If conventional HER2 ligands are used, then clinical imaging is attempted, but renal clearance issues limit applicability
Solution Approach 1:
The patent changes the pharmacokinetic parameters of HER2 ligands by incorporating chelators with specific molecular weights, hydrophilicities, and structural characteristics that optimize renal clearance. This includes selecting chelator sizes and attachment positions that facilitate glomerular filtration while maintaining stable radiolabeling, thereby improving clinical applicability by resolving renal clearance issues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new imaging agents demonstrate higher radiochemical yields, better tumor uptake, and improved renal clearance, facilitating more effective HER2-associated cancer imaging with reduced toxicity.
Implementation Method 1
conjugated with a 99mTc via a diaminedioxime chelator
Implementation Method 2
conjugated with 67Ga or 68Ga via a NOTA chelator
Implementation Method 3
conjugated with 18F via a linker
Implementation Method 4
The isolated polypeptide binds specifically to HER2 or variants thereof
Data Source
AI summary
Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.